Physician profile
Michael D Rokaw
NPI 1154317469
$4,247.73
in general payments reported to CMS, 2019-2025
32 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $264 · 2021: $556 · 2022: $234 · 2023: $418 · 2024: $1,037 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,329 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.43 |
| Education | $174.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $581.43 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $537.38 | 2019-2025 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $365.78 | 2019-2024 | Auryxia, Vafseo |
| Amgen INC. | $365.72 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $316.54 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $309.47 | 2021-2025 | Acthar, Terlivaz |
| Glaxosmithkline, LLC. | $236.45 | 2020-2024 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $225.50 | 2021-2025 | |
| Vifor Pharma, INC. | $190.85 | 2019-2023 | Veltassa |
| Opko Pharmaceuticals, LLC | $168.12 | 2020-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $142.96 | 2025 | |
| Aurinia Pharma U.S., INC. | $90.31 | 2021-2023 | Lupkynis |
| Scpharmaceuticals INC. | $69.85 | 2024-2025 | |
| Veloxis Pharmaceuticals, INC. | $58.89 | 2021-2025 | Envarsus |
| Travere Therapeutics, INC. | $58.50 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $52.99 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $51.31 | 2023-2024 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $48.10 | 2020-2021 | |
| Genzyme Corporation | $47.94 | 2023-2024 | |
| Horizon Therapeutics Plc | $42.20 | 2021-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.63 | 2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $35.37 | 2024-2025 | Ultomiris |
| Daiichi Sankyo INC. | $29.87 | 2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $29.34 | 2019 | |
| Medtronic, INC. | $24.39 | 2025 | Symplicity G3 |
| Shire North American Group INC | $23.62 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.36 | 2023 | Jynarque |
| Novo Nordisk INC | $21.42 | 2024 | Ozempic, Rybelsus |
| Nuwellis, INC. | $17.40 | 2025 | Aquadex Smartflow Console |
| Bard Peripheral Vascular, INC. | $14.77 | 2019 | |
| Medtronic USA, INC. | $14.39 | 2019 | |
| Ani Pharmaceuticals, INC. | $13.88 | 2023 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rokaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.